MOTS-c

A peptide written into your mitochondrial DNA, sent out to manage whole-body metabolism.

Evidence: ELab & animal what's this?
Grade E for use. Strong animal data; human data are correlations, not interventions.
Also known as: Mitochondrial ORF of the 12S rRNA type-c
Class: Mitochondrial-derived peptide (16 amino acids); AMPK activator, exercise mimetic

The 30-second version

WhatDiscovered in 2015. Encoded by mitochondria, not the nucleus. Levels fall with age and insulin resistance.

Why people use itInsulin sensitivity, fat oxidation, exercise capacity and longevity.

The honest catchLow MOTS-c tracks with metabolic disease, but nobody has shown that injecting it fixes that.

What it is

Almost every peptide in this guide is encoded in the cell nucleus. MOTS-c is encoded in the mitochondria’s own small genome, as a signal from the cell’s energy factories to the rest of the body. Exercise raises it, and centenarians tend to have levels like people decades younger. That has earned it the nickname "exercise mimetic".

How it works

Folate cycle is inhibited.

AICAR builds up inside the cell.

AMPK switches on. The same master energy sensor that exercise, metformin and fasting activate.

Muscle effects. GLUT4 moves to the surface for more glucose uptake, more fat oxidation and new mitochondria.

Nucleus. Under stress it enters the nucleus and switches on antioxidant adaptation genes.

What the research shows

In people: the human signal is consistent but correlational. Lower MOTS-c goes with insulin resistance, higher BMI and waist, worse HbA1c and poorer vascular function, and it declines with age². Intervention trials are essentially absent. In animals: MOTS-c prevented age-related and diet-induced insulin resistance and obesity¹, reduced fatty liver, worked with exercise, and improved performance after a single dose³.

It mimics one molecular signal of exercise. It works best alongside training, not instead of it.

Evidence at a glance

Use	Grade	Best evidence	Main gap	Read
Insulin sensitivity	ELab & animal	Prevented insulin resistance and obesity¹	Animal	Strong preclinical
Metabolic biomarker	BHuman trials	Low MOTS-c tracks disease²	Correlation only	Real association
Exercise capacity	ELab & animal	Better performance after one dose³	Animal	Promising
Injected human benefit	DCommunity use	Clinic reports	No trial	Extrapolated

Dosing: what has been reported

Not a recommendation. These figures describe what was studied or what circulates in practice, kept separate so you can see how solid each one is. Speak with a qualified clinician before acting on any of it.

Setting	Figure	Route	Grade
Published human	No intervention dose established	—	—
Clinic / community	Start ~2.5 mg; build over ~4 weeks to 5–10 mg, 3–5× weekly; 8–12 weeks on, 4–6 off	Subcutaneous	D

It’s often timed around training to stack the AMPK effect, or taken in the morning before food on rest days. Its half-life in blood is short, but the downstream effects last longer.

Preparing & storing

Reconstitute with bacteriostatic water, refrigerate and don’t shake.

Reported side effects

Mild hypoglycaemia, especially with other glucose-lowering agents
Injection-site redness
Occasional fatigue, flushing or headache

The benefits are measurable here. Track fasting glucose, HbA1c, insulin/HOMA-IR and body composition.

Who should avoid it

Pregnancy: it acts on the folate cycle, and folate is critical in pregnancy
Methotrexate or other folate-pathway drugs
Diabetes or metformin, berberine or SGLT2 users: monitor glucose
Tested athletes: an AMPK/AICAR-pathway metabolic modulator, likely prohibited

Regulatory status checked Oct 2026

Body	Status	Detail
FDA (US)	Not approved	Under compounding review in 2026.
EMA (EU)	Not approved	—
CDSCO (India)	Not approved	—
WADA	Likely prohibited	Metabolic modulators class; AICAR is explicitly banned.

The NexGen read

A youthful signal worth restoring, if it works

The mechanism is elegant and the animal data are consistent. What’s missing is a human trial that gives MOTS-c and measures the result. Pair it with training and measure your own markers.

References

Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454.
Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. PMC9854231
Hyatt JK. MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance after a single dose. Physiol Rep. 2022;10:e15377.